Drugs / Hu-Mik-Beta-1
Hu-Mik-Beta-1
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT01893775 | Jun 2013 → Dec 2019 | celiac disease | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 1 | NCT00076180 | Mar 2004 → Nov 2010 | T-cell large granular lymphocyte leukemia | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 1 | NCT00076843 | Feb 2004 → Oct 2017 | human T-lymphotropic virus 1 infectious disease | National Institute of Neurological Disorders and Stroke (NINDS) | Completed | No outcome recorded |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Hu-Mik-Beta1 | “A Phase I clinical trial in patients with T-cell LGL and hematocytopenia using the monoclonal antibody, Hu-Mik-Beta-1 that blocks IL-15 action produced under cGMP conditions by...” NCT01893775 ↗4“Hu-Mik-Beta-1 is a genetically engineered antibody that blocks the action of a chemical produced by the body during infection or inflammation called interleukin 15 (IL-15).” NCT00076843 ↗ “This study will examine the use of the humanized Mik-beta-1 (Hu-Mik-beta1) antibody in patients with T-cell large granular lymphocytic leukemia (T-LGL).” NCT00076180 ↗ |
| Known as | Hu Mik-(SqrRoot) 1 | “This study will examine the use of the humanized Mik-Beta-1 (Hu Mik-(SqrRoot) 1) monoclonal antibody in patients with HTLV-1-associated myelopathy/tropical spastic paraparesis...” NCT00076843 ↗ |
| Known as | Hu-Mikβ1 | “In the present study, Hu-Mikβ1, a humanized mAb directed at the shared IL-2/IL-15Rβ subunit (CD122) was evaluated in patients with T-cell large granular lymphocytic (T-LGL) leukemia.” PMID 23212516 ↗ Dec 2012 |
| Known as | Mik-Beta-1 | “This study will examine the use of the humanized Mik-Beta-1 (Hu Mik-(SqrRoot) 1) monoclonal antibody in patients with HTLV-1-associated myelopathy/tropical spastic paraparesis...” NCT00076843 ↗ |
| Action | Inhibit | “Hu-Mik-Beta1 may inhibit the growth and exert cytotoxic activity against T-LGL cells.” NCT00076180 ↗ |
| Modality | Monoclonal antibody | “Hu-Mik-Beta1 is a humanized monoclonal antibody that binds to IL-2R/IL-15R Beta” NCT00076180 ↗ |
| Route | Intravenous | “Hu-MiK-Beta-1 administered as an intravenous infusion over 90- minutes.” NCT00076180 ↗ |